Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.

Cancer research and treatment - 1 Jan 2022

Lee Chaelin, Kim Miso, Kim Dong-Wan, Kim Tae Min, Kim Soyeon, Im Sun-Wha, Jeon Yoon Kyung, Keam Bhumsuk, Ku Ja-Lok, Heo Dae Seog

Abstract excerpt

PURPOSE: Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non-small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance mechanism of EGFR-KDD against EGFR-TKIs. MATERIALS AND METHODS: We identified EGFR-KDD in tumor tissue obtained from a patient with stage IV lung adenocarcinoma and established the patient-derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 33940786
DOI: 10.4143/crt.2021.385
PMCID: PMC8756122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.PMID 33940786Read ↗

Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review.Semantic proximity Read ↗

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLCSemantic proximity Read ↗

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.Semantic proximity Read ↗

Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.Semantic proximity Read ↗

Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.Semantic proximity Read ↗

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.Semantic proximity Read ↗

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Semantic proximity Read ↗

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.Semantic proximity Read ↗

Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib.Semantic proximity Read ↗

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer.Semantic proximity Read ↗

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.